Also known as A-4 cartilage peptide · cartilage / bone peptide complex
A natural cartilage and bone peptide complex (Cytomax A-4) from the Khavinson bioregulator line, marketed for joint and connective-tissue support.
Research refreshed
Sigumir is a natural peptide complex extracted from cartilage and bone tissue (peptide complex A-4), part of the Russian Cytomax / Revilab bioregulator line. It is marketed within the Khavinson tradition for joint, cartilage, and connective-tissue support, with no defined synthetic short-peptide counterpart in the catalog.
Sigumir is the cartilage- and bone-directed natural bioregulator of the Cytomax / Revilab line, extracted from connective tissue. Unlike the thymic, vascular, or cardiac entries, it has no defined synthetic Cytogen counterpart in this catalog — the extract is the only form marketed within the tradition.
As a tissue extract it is a standardized polypeptide fraction with no single molecular formula or sequence. Its joint and connective-tissue claims come from the same concentrated research tradition as the rest of the series, with limited independent replication, and it is not FDA-approved.
Proposed tissue-selective (bioregulator) modulation of chondrocyte / osteoblast gene expression, in the Cytomax extract tradition.
Behind every vial of Sigumir is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Sigumir, specifically, is brought into being.
Sigumir begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Sigumir is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Sigumir plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Sigumir proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Sigumir — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Sigumir is a natural cartilage and bone peptide extract (complex A-4), a fractionated polypeptide preparation rather than a synthesized peptide. Consistency and characterization of the extract, not coupling chemistry, determine its quality.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Sigumir is a natural cartilage and bone peptide complex (Cytomax A-4), marketed for joint and connective-tissue support within the Khavinson bioregulator tradition.
No — unlike the thymic, vascular, or cardiac Cytomaxes, Sigumir has no defined synthetic Cytogen peptide in this catalog; the tissue extract is the only marketed form.
No — it is a tissue extract (a polypeptide fraction), so it has no single sequence or molecular formula.
No — it is a research compound / supplement, not FDA-approved. This page is a research and educational reference.
Synthetic gastric pentadecapeptide investigated for tendon, ligament, and GI repair.
ViewSynthetic fragment of thymosin β4 studied for cell migration and tissue repair.
ViewA 27-residue single-chain relaxin-2 analog and selective RXFP1 agonist — a simplified relaxin mimetic studied for anti-fibrotic effects.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.